.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Citi
US Army
Moodys
McKesson
Merck
Dow
Daiichi Sankyo
Johnson and Johnson

Generated: November 24, 2017

DrugPatentWatch Database Preview

Empagliflozin; metformin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for empagliflozin; metformin hydrochloride and what is the scope of empagliflozin; metformin hydrochloride patent protection?

Empagliflozin; metformin hydrochloride
is the generic ingredient in two branded drugs marketed by Boehringer Ingelheim and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Empagliflozin; metformin hydrochloride has one hundred and twenty-seven patent family members in thirty-four countries and fourteen supplementary protection certificates in twelve countries.

There are five drug master file entries for empagliflozin; metformin hydrochloride. One supplier is listed for this compound.

Summary for empagliflozin; metformin hydrochloride

Pharmacology for empagliflozin; metformin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL206111-003Aug 26, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-001Dec 9, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-003Dec 9, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-004Dec 9, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Boehringer Ingelheim
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL206111-001Aug 26, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-002Dec 9, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL206111-001Aug 26, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL206111-001Aug 26, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-002Dec 9, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Boehringer Ingelheim
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL206111-004Aug 26, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: empagliflozin; metformin hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,687,469Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: empagliflozin; metformin hydrochloride

Country Document Number Estimated Expiration
South Africa200605511► Subscribe
World Intellectual Property Organization (WIPO)2006117359► Subscribe
SloveniaEP1730131► Subscribe
China1930141► Subscribe
Peru15892009► Subscribe
Norway335264► Subscribe
HungaryS1400056► Subscribe
Japan4226070► Subscribe
South Korea101249711► Subscribe
Slovenia1888552► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0074France► SubscribePRODUCT NAME: EMPAGLIFLOZINE ET SES SELS, EN PARTICULIER L'EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930 20140522
0 5026-2014Slovakia► SubscribePRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/14/930 20140527
14/055Ireland► SubscribePRODUCT NAME: EMPAGLIFLOZIN AND SALTS THEREOF, IN PARTICULAR EMPAGLIFLOZIN ((1S)-1,5- ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXOLAN-3-YL)OXY))PHENYL)METHYL)PHENYL)- D-GLUCITOL); REGISTRATION NO/DATE: EU/1/14/930 20140522
1730131/02Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
2014035Lithuania► SubscribePRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
2014 00054Denmark► SubscribePRODUCT NAME: EMPAGLIFLOZIN OG SALTE DERAF, SAERLIGT EMPAGLIFLOZIN; REG. NO/DATE: EU1/14/930/001/018 20140522
2014000099Germany► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND DESSEN SALZE, INSBESONDERE EMPAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/14/930 20140522
2014035,C1730131Lithuania► SubscribePRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
90061-7Sweden► SubscribePRODUCT NAME: EMPAGLIFLOZIN AND SALTS THEREOF, IN PARTICULAR EMPAGLIFLOZIN; REG. NO/DATE: EU/1/14/930 20140522
00696Netherlands► SubscribePRODUCT NAME: EMPAGLIFLOZINE EN ZOUTEN DAARVAN, IN HET BIJZONDER EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930/001-009 20140522
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Novartis
Boehringer Ingelheim
Healthtrust
Teva
Mallinckrodt
Chubb
Accenture
AstraZeneca
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot